Hikma Pharmaceuticals announces $1bn investment to expand U.S. manufacturing

In its ongoing mission to help meet America’s growing need for high-quality US-made medicines, Hikma Pharmaceuticals USA has announced it will invest $1bn by 2030 to further expand its US manufacturing and R&D capabilities.  

This new phase of investment – America Leans on Hikma: Quality Medicines Manufactured in the USA – will further expand Hikma’s well-established domestic capabilities to develop, produce and deliver a broad range of medicines needed by the US healthcare system to treat patients nationwide.

Hikma has operated in the US since 1991 and has spent more than $4bn over the past 15 years to build, enhance and expand its US-based R&D and manufacturing capabilities and now has annual domestic capacity to produce more than 12 billion finished doses of essential medicines. Over this period, Hikma has provided patients with access to a wide range of generic medicines at a lower cost than branded products.  The company has an excellent record of US FDA quality inspections and has a successful record of working with FDA to solve critical drug shortages.

Elected officials, including US Rep. Mike Carey (OH-15) and US Rep. Buddy Carter (GA-01), joined Hikma at a special groundbreaking event held at the Company’s state-of-the-art pharmaceutical manufacturing and R&D facility in Columbus, Ohio.

America Leans on Hikma represents the Company’s latest efforts to increase the volume of essential medicines it develops and produces across its R&D and manufacturing sites in Columbus and Cleveland, Ohio and in Cherry Hill and Dayton, New Jersey. This next phase of expansion will help to strengthen Hikma’s portfolio of more than 800 medicines and increase the Company’s US-based capacity to produce large volumes of high-quality and affordable medicines for American hospitals, providers and patients.

“We are proud to continue our ongoing investments in US manufacturing and R&D to better serve the needs of American patients,” said Dr. Hafrun Fridriksdottir, President, Hikma Rx. “Hikma and our 2,300 dedicated US people are committed to supporting healthier communities nationwide by providing Americans with a steady and reliable supply of domestically produced quality medicines.”